THE USE OF SUMATRIPTAN IN THE TREATMENT OF MIGRAINE
- 1 July 1993
- journal article
- review article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 47 (4) , 205-207
- https://doi.org/10.1111/j.1742-1241.1993.tb09665.x
Abstract
Sumatriptan is a selective agonist of 5-hydroxytryptamine receptors, recommended for the acute treatment of migraine. The 5-HT1 receptor subtype is found in the cranial vasculature of many species including humans, and causes vasoconstriction of these vessels. Sumatriptan as a highly potent 5-HT1 agonist selectively constricts large intracranial blood vessels and also blocks neurogenic inflammation. Those treating patients with severe or inconveniently timed attacks will find sumatriptan the drug of choice.This publication has 26 references indexed in Scilit:
- Transmural myocardial infarction with sumatriptanThe Lancet, 1993
- Effect of Sumatriptan, a Selective 5-HT1-like Receptor Agonist, on Pial Vessel Diameter in Anaesthetised CatsJournal of Cerebral Blood Flow & Metabolism, 1992
- Treatment of Acute Cluster Headache with SumatriptanNew England Journal of Medicine, 1991
- Treatment of Migraine Attacks with SumatriptanNew England Journal of Medicine, 1991
- Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptanThe Lancet, 1991
- Treatment of Acute Migraine With Subcutaneous SumatriptanJAMA, 1991
- Subcutaneous sumatriptan in the acute treatment of migraineZeitschrift für Neurologie, 1991
- The Vasoconstrictor Action of Sumatriptan on Human Isolated Dura MaterPublished by Springer Nature ,1991
- Lack of Antinociceptive Activity of Sumatriptan in RodentsCephalalgia, 1990
- The concept of selectivity in 5-HT receptor researchEuropean Journal of Pharmacology: Molecular Pharmacology, 1990